Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessprotein-containing complex disassembly

APC LMOD3 CHMP4A ATAD2 RUBCN

3.38e-05291275GO:0032984
GeneOntologyBiologicalProcessregulation of protein localization to centrosome

APC CEP72

1.08e-0412272GO:1904779
MousePhenoincreased fibroblast apoptosis

DCAF1 RAD54L2 BIRC6

3.20e-0544203MP:0013501
MousePhenoabnormal fibroblast apoptosis

DCAF1 RAD54L2 BIRC6

8.98e-0562203MP:0013500
Domain-

IMPACT BIRC6

2.64e-03512823.10.110.10
DomainUBQ-conjugating_enzyme/RWD

IMPACT BIRC6

2.85e-0353282IPR016135
Domain-

DCAF1 APC ATAD2

4.36e-032222831.25.10.10
DomainARM-like

DCAF1 APC ATAD2

7.49e-03270283IPR011989
DomainHELICASE_CTER

DHX32 RAD54L2

1.16e-02109282PS51194
DomainHELICASE_ATP_BIND_1

DHX32 RAD54L2

1.16e-02109282PS51192
DomainHelicase_ATP-bd

DHX32 RAD54L2

1.18e-02110282IPR014001
Domain-

DCAF1 TAF5L BIRC6

1.32e-023332832.130.10.10
DomainWD40/YVTN_repeat-like_dom

DCAF1 TAF5L BIRC6

1.34e-02335283IPR015943
DomainARM-type_fold

DCAF1 APC UPF2

1.39e-02339283IPR016024
Pubmed

A conserved acetylation switch enables pharmacological control of tubby-like protein stability.

RAD54L2 BIRC6 GLG1 SENP7

3.45e-0522329433187986
Pubmed

CRL7SMU1 E3 ligase complex-driven H2B ubiquitylation functions in sister chromatid cohesion by regulating SMC1 expression.

DCAF1 APC

1.02e-041829229507117
Pubmed

Epistatic interactions between NMD and TRP53 control progenitor cell maintenance and brain size.

GADD45B UPF2

1.53e-042229238697111
Pubmed

Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.

APC TIMELESS RAD54L2 UPF2 RUBCN

1.84e-0465029538777146
Pubmed

Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions.

DCAF1 APC GADD45B TIMELESS MRS2 ATAD2

5.94e-04129329615342556
Cytoband3p21.2

DCAF1 RAD54L2

6.54e-05192923p21.2
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; PC3; HT_HG-U133A

APC GADD45B CEP72 INPP4A TTLL7

2.76e-061842857295_UP
DrugHelveticoside [630-64-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A

IMPACT MRS2 INPP4A PUS7L

7.26e-051842843945_DN
DrugGalanthamine hydrobromide [1953-04-4]; Up 200; 10.8uM; HL60; HT_HG-U133A

DCAF1 INPP4A SENP7 TTLL7

8.74e-051932842131_UP
DrugFlumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A

APC TIMELESS TEX15 INPP4A

8.74e-051932843712_DN
DrugProglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A

APC TIMELESS CEP72 GLG1

8.91e-051942843861_DN
DrugDienestrol [84-17-3]; Up 200; 15uM; MCF7; HT_HG-U133A

GADD45B CEP72 GLG1 INPP4A

8.91e-051942846208_UP
DrugVerteporfin [129497-78-5]; Up 200; 2.8uM; MCF7; HT_HG-U133A

DCAF1 APC LAMB4 INPP4A

8.91e-051942843556_UP
Drugchlorpromazine hydrochloride; Up 200; 10uM; MCF7; HG-U133A

APC GADD45B PDE6A GLG1

9.09e-05195284419_UP
DrugChenodiol [474-25-9]; Up 200; 10.2uM; PC3; HT_HG-U133A

APC MRS2 SENP7 TTLL7

9.28e-051962847310_UP
DrugMeclofenamic acid sodium salt monohydrate [6385-02-0]; Down 200; 11.8uM; MCF7; HT_HG-U133A

APC GLG1 INPP4A SENP7

9.28e-051962842291_DN
DrugPiperidolate hydrochloride [129-77-1]; Down 200; 11.2uM; MCF7; HT_HG-U133A

IMPACT APC INPP4A PUS7L

9.28e-051962846772_DN
DrugPregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A

APC TIMELESS RAD54L2 GLG1

9.28e-051962844802_DN
DrugSB 202190; Up 200; 1uM; MCF7; HT_HG-U133A

APC RAD54L2 CEP72 RUBCN

9.28e-051962847054_UP
DrugFolic acid [59-30-3]; Down 200; 9uM; MCF7; HT_HG-U133A

APC TAF5L INPP4A SENP7

9.46e-051972842783_DN
DrugVincamine [1617-90-9]; Down 200; 11.2uM; PC3; HT_HG-U133A

TIMELESS TAF5L INPP4A SENP7

9.46e-051972843784_DN
DrugCefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A

DCAF1 IMPACT APC RAD54L2

9.46e-051972842235_DN
DrugUngerine nitrate; Down 200; 10.2uM; HL60; HT_HG-U133A

IMPACT CEP72 GLG1 RUBCN

9.46e-051972842514_DN
DrugTheobromine [83-67-0]; Down 200; 22.2uM; MCF7; HT_HG-U133A

APC GADD45B GLG1 INPP4A

9.46e-051972843334_DN
DrugTremorine dihydrochloride [300-68-5]; Down 200; 15uM; HL60; HG-U133A

IMPACT GADD45B TIMELESS MRS2

9.65e-051982841579_DN
DrugAcebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

APC TIMELESS TAF5L SENP7

9.65e-051982841493_UP
DrugPipemidic acid [51940-44-4]; Down 200; 13.2uM; MCF7; HT_HG-U133A

DCAF1 APC GLG1 INPP4A

9.84e-051992846470_DN
Drugkojic acid

GADD45B CEP72 UBR7 ZC3H15 PUS7L

1.51e-04424285ctd:C011890
DiseaseProfound Mental Retardation

APC UBR7 INPP4A

3.42e-04139293C0020796
DiseaseMental deficiency

APC UBR7 INPP4A

3.42e-04139293C0917816
DiseaseMental Retardation, Psychosocial

APC UBR7 INPP4A

3.42e-04139293C0025363
DiseaseMalignant Neoplasms

APC BIRC6

7.02e-03128292C0006826
Diseasemacrophage inflammatory protein 1b measurement

DCAF1 RAD54L2

7.89e-03136292EFO_0008219
DiseaseIntellectual Disability

APC UBR7 INPP4A

9.42e-03447293C3714756

Protein segments in the cluster

PeptideGeneStartEntry
VDEDELLEELEELEQ

CHMP4A

156

Q9BY43
ILDNREDDCEEPIED

BIRC6

866

Q9NR09
EELDEDFEQLCEEIQ

ATAD2

1091

Q6PL18
DADDEAVLNLIAECE

CEP72

191

Q9P209
VAVEECDRDDEEDLL

RAD54L2

31

Q9Y4B4
DGDEEEVLACEDLEL

DHX32

26

Q7L7V1
LLEEDAARVCELEEL

INPP4A

266

Q96PE3
ELDTDQLLEAELEED

DCAF1

1426

Q9Y4B6
QLQDLEECREELDTD

LZIC

26

Q8WZA0
EELLDEEINEDEILA

LMOD3

11

Q0VAK6
ECEEEELAEILQAEL

PDE6A

481

P16499
LEILDEEELLEELCV

MRS2

256

Q9HD23
EVEELLDEVEELLEQ

GOLGA6L4

406

A6NEF3
EEEDVECEDDLILAC

IMPACT

131

Q9P2X3
ELECLQDHLDDLVVE

GLG1

656

Q92896
LCLLAIDEEEEDDIA

GADD45B

56

O75293
EADLLLEDLQEEIDL

LAMB4

1281

A4D0S4
QCLEEEEVEEEDSDR

RUBCN

516

Q92622
DDLELELENLEINDD

UPF2

516

Q9HAU5
LACDILEEEDDEDDN

TAF5L

316

O75529
DLECLEEGEFLNDVI

SENP7

766

Q9BQF6
QGDLVCLDEDIDDEN

PUS7L

556

Q9H0K6
DSDDDDIEILEECII

APC

1566

P25054
ESLKDFCQEDLEEEE

TIMELESS

961

Q9UNS1
VDVLEEDEELENEAC

UBR7

21

Q8N806
DLDELEEELNTLDLE

ZC3H15

411

Q8WU90
SIELESEIEIELEDC

TEX15

671

Q9BXT5
SEIEIELEDCDDAFI

TEX15

676

Q9BXT5
EDLVLTCEDDEDEEL

ZBTB22

326

O15209
EEDILDLLEQCEIDD

TTLL7

501

Q6ZT98